INOVIO Pharmaceuticals, Inc. — Q1 2013 Form 10-Q
Period: Three months ended March 31, 2013; balance-sheet comparisons are with December 31, 2012. Inovio develops DNA-based vaccines and immune therapies for cancer and infectious diseases, using its SynCon technology and electroporation delivery systems. All human product candidates remained in research and development; the company reported no product-sales revenue.
Key financial results
| Metric | Q1 2013 | Q1 2012 / prior date |
|---|---|---|
| Total revenue | $1.46 million | $1.69 million |
| Operating expenses | $8.09 million | $5.88 million |
| Operating loss | $6.63 million | $4.19 million |
| Net loss attributable to Inovio | $8.84 million | $8.25 million |
| Basic and diluted loss per share | $0.06 | $0.06 |
| Cash used in operating activities | $5.13 million | $5.44 million |
| Cash and cash equivalents | $20.09 million | $5.65 million at Dec. 31, 2012 |
| Short-term investments | $7.98 million | $8.03 million at Dec. 31, 2012 |
| Working capital | $14.3 million | $7.6 million at Dec. 31, 2012 |
| Accumulated deficit | $238.6 million | $229.8 million at Dec. 31, 2012 |
Revenue was primarily grants and miscellaneous revenue ($1.33 million); license and milestone revenue was $121,000. The filing reports no separate debt balance; current liabilities include a $10.25 million warrant liability. Total liabilities were $17.78 million at March 31, 2013.
Changes and financing
- Revenue declined about 14% year over year, principally because NIAID contract revenue fell to $1.0 million from $1.5 million; PATH revenue and a Department of Defense grant partly offset the decline.
- Research and development expense increased to $5.12 million from $4.04 million, mainly due to higher HPV-003 clinical-trial costs, increased headcount, and NIAID work. General and administrative expense rose to $2.97 million from $2.49 million, including $316,000 of warrant-issuance costs and higher legal fees.
- The operating loss widened, while net loss increased more modestly. A $1.43 million warrant revaluation expense was lower than the $3.55 million charge in Q1 2012; the company also recorded an $836,000 loss on its investment in affiliate VGX International.
- Financing activities provided $19.56 million. The March underwritten offering generated approximately $14.0 million net proceeds; the ATM program generated $5.6 million net proceeds from 8.22 million shares sold. Common shares outstanding increased from 144.31 million at year-end to 179.94 million at quarter-end. The offering also issued warrants to buy 13.69 million shares.
Outlook, risks, and unusual items
- Management believed cash and short-term investments were sufficient for planned working-capital needs through the fourth quarter of 2014. The company expects continued operating losses and reliance on external financing thereafter; it cautioned it may never achieve positive cash flow or profitability.
- Inovio said it expects no product revenue for at least several years. Performance depends on clinical and regulatory progress, manufacturing, grants and collaborations, and access to additional capital. Clinical outcomes are uncertain, and no human vaccine product candidate had regulatory approval.
- Revenue concentration, potential grant or government-contract termination, clinical-trial delays or failures, competition, intellectual-property disputes, manufacturing risks, and future financing and dilution are material risks identified in the filing.
- Registered warrants are remeasured at fair value using a model with significant assumptions; the $10.25 million quarter-end liability and related earnings charge can change with share price and valuation inputs.
- In April 2013, the company entered a ten-year San Diego office and R&D lease, with monthly base rent ranging from zero to $82,945, plus operating expenses and a management fee.
- Management reported effective disclosure controls as of March 31, 2013, with no material change in internal control over financial reporting during the quarter. Legal proceedings were reported as not applicable.
Important facts for investors to verify
- Whether the stated cash runway through Q4 2014 remains supportable given the rate of research, clinical, and administrative spending.
- Progress, costs, enrollment, and results of the HPV-003 trial and other clinical programs, alongside the timing and continued funding of NIAID and other collaborations.
- Potential dilution from the 35.23 million warrants outstanding at quarter-end, options, and further use of the ATM facility.
- The assumptions behind the warrant liability and fair-value changes, and developments affecting the VGX International investment.
- The financial commitments and occupancy plans associated with the new ten-year lease.